Hodgkin Lymphoma
From the Journals
Physical inactivity linked to lymphoma risk
Individuals who engaged in exercise less than once a week over their lifetime had an increased risk of Hodgkin and non-Hodgkin lymphoma.
News
Umbralisib has ‘distinct’ safety profile
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell...
News
‘Long-term benefits’ with nivolumab in cHL
Nivolumab can provide “long-term benefits” in patients with relapsed or refractory classical Hodgkin lymphoma (cHL), according to researchers....
Conference Coverage
Novel targeted cancer drugs cause fewer arrhythmias
Tyrosine kinase inhibitors and other targeted agents have 40% lower cardiac arrhythmia risk than anthracycline-based regimens.
News
CHMP recommends approval for generic carmustine
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Carmustine Obvius, a...
News
FDA places tazemetostat trials on partial hold
The hold has halted enrollment in US-based trials of tazemetostat, but study subjects who have not experienced disease progression may continue to...
News
Art education benefits blood cancer patients
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including...
News
FDA approves BV plus chemo for untreated cHL
The US Food and Drug Administration (FDA) has approved brentuximab vedotin (ADCETRIS) in combination with chemotherapy for adults with previously...
News
FDA approves new option in Hodgkin lymphoma treatment
The approval is based on results from the ECHELON-1 trial in previously untreated patients with stage III or IV classical Hodgkin lymphoma.
News
Lymphoma, breast cancer survivors have greater risk of CHF
ORLANDO—Results of a retrospective study showed that survivors of lymphoma or breast cancer had a significantly greater risk of congestive heart...
News
FDA approves label update for nivolumab
The US Food and Drug Administration (FDA) has updated the label for nivolumab (Opdivo®) to include new dosing and administration information....